This file contains the tables for the datasets and methods we benchmarked.

**Table1.** Datasets summary

| **Datasetssummary** |
| --- |
| **Dataset (name usedinthispaper)** | **Number ofobservations** | **No. ofvariables** | **Type ofdata** | **Censoringrate(rounded to 4decimalplaces)** **Reference** |

| Melanoma\_itraq | 41 | 642 | Omics | 0.4146 | Wang,K.Y.X. et al. Cross-Platform Omics Prediction procedure: agame changer for implementing precision medicine in patientswithstage-IIImelanoma.bioRxiv2020.12.09.415927;doi:[https://doi.org/10.1101/2020.12.09.415927](https://doi.org/10.1101/2020.12.09.415927) |

| Melanoma\_nano | 45 | 206 | Omics | 0.4222 | Wang,K.Y.X. et al. Cross-Platform Omics Prediction procedure: agame changer for implementing precision medicine in patientswithstage-IIImelanoma.bioRxiv2020.12.09.415927;doi:[https://doi.org/10.1101/2020.12.09.415927](https://doi.org/10.1101/2020.12.09.415927) |
| Ovarian\_2 | 58 | 19818 | Omics | 0.3793 | Ganzfried,B.F.etal.(2013)curatedOvarianData:clinicallyannotateddatafortheovariancancertranscriptome.Database,2013. |
| GE\_5 | 78 | 4753 | Omics | 0.5641 | van&#39;tVeer,L.J.etal.(2002)Geneexpressionprofilingpredictsclinical outcomeofbreast cancer.Nature,415,530–536. |
| GE\_3 | 86 | 6288 | Omics | 0.7209 | Bullinger,L.etal.(2004)UseofGene-ExpressionProfilingtoIdentifyPrognostic Subclasses in Adult Acute Myeloid Leukemia. NewEnglandJournalofMedicine,350, 1605–1616. |
| Melanoma\_clinical | 88 | 16 | Clinical | 0.3939 | Wang,K.Y.X. et al. Cross-Platform Omics Prediction procedure: agame changer for implementing precision medicine in patientswithstage-IIImelanoma.bioRxiv2020.12.09.415927;doi:[https://doi.org/10.1101/2020.12.09.415927.](https://doi.org/10.1101/2020.12.09.415927) |
| GE\_1 | 115 | 551 | Omics | 0.6670 | Sorlie,T. et al. (2003) Repeated observation of breast tumor subtypesin independent gene expression data sets. Proc. Natl. Acad. Sci.U.S. A., 100, 8418–8423. |
| GE-\_4 | 116 | 6285 | Omics | 0.5641 | van de Vijver,M.J. et al. (2002) A gene-expression signature as apredictorofsurvivalinbreastcancer.N.Engl.J.Med.,347,1999–2009. |
| Veteran | 137 | 8 | Clinical | 0.0657 | Kalbfleisch,J.D.andPrentice,R.L.(2002)TheStatisticalAnalysisofFailureTimeData.WileySeriesinProbabilityandStatistics. |
| Ovarian\_1 | 194 | 16050 | Omics | 0.7062 | Ganzfried,B.F.etal.(2013)curatedOvarianData:clinicallyannotateddatafortheovariancancertranscriptome.Database,2013. |
| Lung | 228 | 9 | Clinical | 0.2763 | Loprinzi,C.L.etal.(1994)Prospectiveevaluationofprognosticvariables from patient-completed questionnaires. North CentralCancerTreatment Group.J. Clin.Oncol., 12,601–607. |
| GE\_6 | 240 | 7401 | Omics | 0.4250 | Van Houwelingen,H.C. (2004) The Elements of Statistical Learning,Data Mining, Inference, and Prediction. Trevor Hastie, RobertTibshirani and Jerome Friedman, Springer, New York, 2001. No.of pages: xvi 533. ISBN 0-387-95284-5. Statistics in Medicine,23, 528–529. |
| GE\_2 | 295 | 4921 | Omics | 0.7322 | Beer,D.G.etal.(2002)Gene-expressionprofilespredictsurvivalofpatientswithlungadenocarcinoma.Nat.Med.,8,816–824. |
| PBC | 312 | 7 | Clinical | 0.5994 | Fleming,T.R.andHarrington,D.P.(2005)CountingProcessesandSurvivalAnalysis.WileySeriesinProbabilityandStatistics. |
| UNOS\_Kidney | 3000 | 101 | Clinical | 0.7350 | OPTNdata (https://optn.transplant.hrsa.gov/) |
| ANZ | 3323 | 40 | Clinical | 0.8739 | ANZDATA (https://www.anzdata.org.au/) |

Data table showing the names of datasets used in this paper in the first column. Datasets are ordered by the number ofobservations(secondcolumn,fromsmallest to largest).Censoring rateisroundedto 4decimal places.

